XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Statements of Operations (Unaudited) (Brooklyn ImmunoTherapeutics, LLC) - USD ($)
 2 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Nov. 05, 2018
Dec. 31, 2019
Operating Expenses          
Research and development         $ 26,000
Total operating expenses   $ 10,196,000 $ 15,173,000   21,568,000
Loss from operations   (5,571,000) (535,000)   (1,762,000)
Other Expenses          
Net loss   (4,722,000) (754,000)   (2,047,000)
Net income attributable to common stockholders   (4,730,000) (762,000)   (2,063,000)
Brooklyn Immunotherapeutics, LLC [Member]          
Operating Expenses          
General and administrative   4,032,690 3,489,936    
Research and development   1,008,631 2,600,199    
Total operating expenses   5,041,321 6,090,135    
Loss from operations   (5,041,321) (6,090,135)    
Other Expenses          
Interest expense, net   31,482 44,254    
Total other expense, net   (31,482) (44,254)    
Net loss   $ (5,072,803) $ (6,134,389)   8,937,054
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member]          
Operating Expenses          
General and administrative $ 374,267       3,721,490
Research and development 1,621,084       5,156,266
Total operating expenses 1,995,351       8,877,756
Loss from operations (1,995,351)       (8,877,756)
Other Expenses          
Interest expense, net (9,121)       (59,298)
Total other expense, net (9,121)       (59,298)
Net loss $ (2,004,472)       $ (8,937,054)
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member]          
Operating Expenses          
General and administrative       $ 5,351,698  
Research and development       9,078,193  
Total operating expenses       14,429,891  
Loss from operations       (14,429,891)  
Other Expenses          
Interest expense, net       (1,668,711)  
Total other expense, net       (1,668,711)  
Net loss       (16,098,602)  
Deemed dividends on preferred stock       (685,892)  
Gain on extinguishment of preferred stock.       106,560,811  
Net income attributable to common stockholders       $ 89,776,317